Pierre Boulud joins STERIS (NYSE: STE) board as company expands seats

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

STERIS plc reported changes to its Board of Directors. Long-serving director Richard C. Breeden will retire and not stand for reelection at the 2026 Annual General Meeting, with the company noting his decision is not due to any disagreement over operations, policies or practices.

The Board increased its size from nine to ten members and appointed Pierre Boulud, CEO of bioMérieux, as a director effective May 5, 2026. He brings experience in in vitro diagnostics, biopharma and strategy roles. Boulud will receive a prorated fee of $76,989 for the 2025-26 Board term, paid in career restricted stock units under STERIS’s Non-Employee Director Compensation Program.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Board size after change: 10 members Director prorated fee: $76,989 Breeden board service: 18 years +2 more

5 metrics

Board size after change 10 members Board increased from nine to ten members effective May 5, 2026

Director prorated fee $76,989 Compensation for Pierre Boulud for remainder of 2025-26 Board term, paid in RSUs

Breeden board service 18 years Length of Richard C. Breeden’s service as STERIS director before retirement

Pierre Boulud age 54 Age of new STERIS director at time of appointment

bioMérieux CEO tenure since 2023 Pierre Boulud’s role as CEO of bioMérieux

Key Terms

career restricted stock units, Non-Employee Director Compensation Program, in vitro diagnostics, forward-looking statements, +1 more

5 terms

career restricted stock units financial

"fee of $76,989 ... payable in career restricted stock units granted in conjunction"

Non-Employee Director Compensation Program financial

"career restricted stock units granted in conjunction with the Company’s Non-Employee Director Compensation Program"

in vitro diagnostics technical

"bioMérieux, a biotechnology company focused on in vitro diagnostics"

In vitro diagnostics are medical tests performed on samples taken from the body—such as blood, urine or tissue—using instruments or kits outside the patient to detect disease, measure biomarkers or guide treatment decisions. They matter to investors because sales, regulatory approvals, reimbursement rules and adoption rates drive companies’ revenue and margins much like product launches and consumer demand in other industries; advances can create growth or disruption in healthcare markets.

forward-looking statements regulatory

"forward-looking information ... intended to qualify for the protections afforded “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

ethylene oxide litigation regulatory

"including the ethylene oxide litigation, may delay, limit or prevent new product"

Understanding 8-K Material Events →

05/07/2026 - 04:35 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2026

STERIS plc

(Exact Name of Registrant as Specified in Charter)

Ireland

001-38848

98-1455064

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(IRS Employer

Identification No.)

70 Sir John Rogerson’s Quay, Dublin 2, Ireland D02 R296

(Address of principal executive offices)

Registrant’s telephone number, including area code: + 353 1 232 2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, $0.001 par value	STE	New York Stock Exchange
2.700% Senior Notes due 2031	STE/31	New York Stock Exchange
3.750% Senior Notes due 2051	STE/51	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Breeden’s decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s operations, policies or practices. The Company and the Board thank Mr. Breeden for his 18 years of service to the Company as a Director.

On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date.

Mr. Boulud, age 54, is the Chief Executive Officer of bioMérieux, a biotechnology company focused on in vitro diagnostics, having served in that role since June 2023. Mr. Boulud joined bioMérieux in 2016 as Corporate Vice President, Head of Asia Pacific Region, and was promoted to Chief Operating Officer in 2020. Previously, he worked at Ipsen, a pharmaceutical company, from 2002 until 2016, serving in various roles of increasing responsibility and ultimately as the Executive Vice President of Specialty Care Commercial Operations. Mr. Boulud began his career as a strategic consultant, working at Bossard Consultants from 1995 to 1997 and at the Boston Consulting Group from 1997 to 2002.

Mr. Boulud will receive a prorated fee of $76,989 for the remainder of the Board’s 2025-26 term of office, which will be payable in career restricted stock units granted in conjunction with the Company’s Non-Employee Director Compensation Program. Mr. Boulud will be eligible for the same indemnification program as the other members of the Board.

Item 7.01

Regulation FD Disclosure.

On May 7, 2026, the Company issued a press release announcing Mr. Boulud’s appointment. The press release is attached hereto as Exhibit 99.1.

The information contained in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits:


Exhibit No.		Description

99.1		Press Release issued by STERIS plc on May 7, 2026 announcing the appointment of Mr. Boulud

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


STERIS plc

By		/s/ J. Adam Zangerle
Name:		J. Adam Zangerle
Title:		Senior Vice President, General Counsel & Company Secretary

Dated: May 7, 2026

Exhibit 99.1

STERIS Appoints Pierre Boulud to Board of Directors

DUBLIN, IRELAND, May 7, 2026 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that, effective May 5, 2026, Pierre Boulud has been appointed to the Board of Directors.

“We are pleased to welcome Pierre to our Board,” said Mohsen Sohi, Chairman of STERIS. “His leadership experience, global perspective, strategic acumen, and operational expertise make him an excellent addition to the Board.”

Boulud is CEO of bioMérieux, a world leader in the field of in vitro diagnostics, a role he has held since 2023. Boulud joined bioMérieux in 2016 as Corporate Vice President, Head of Asia Pacific Region, and was promoted to Chief Operating Officer in 2020. Prior to joining bioMérieux, he spent fourteen years at Ipsen, a global specialty-driven biotechnological group, culminating in his role as Executive Vice President of Specialty Care Commercial Operations, where he had responsibility for global sales of this division. Prior to that, Boulud worked as a strategic consultant at The Boston Consulting Group.

About STERIS

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences products and services. For more information, visit www.steris.com.

Company Contact:

Julie Winter, Vice President, Investor Relations and Corporate Communications

Julie_Winter@steris.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.

Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the ethylene oxide litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than

anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

Source: View Original Filing on SEC EDGAR

FAQ

What board changes did STERIS (STE) announce in this 8-K?

STERIS announced that long-time director Richard C. Breeden will retire and not stand for reelection at the 2026 Annual General Meeting. The Board also expanded from nine to ten members and appointed bioMérieux CEO Pierre Boulud as a new director effective May 5, 2026.

Why is Richard C. Breeden leaving the STERIS (STE) board?

Richard C. Breeden notified STERIS that he will not stand for reelection at the 2026 Annual General Meeting, effectively retiring after 18 years on the Board. The company stated his decision is not due to any disagreement regarding STERIS’s operations, policies or practices.

Who is Pierre Boulud, the new STERIS (STE) director?

Pierre Boulud is the CEO of bioMérieux, a global in vitro diagnostics company, a role he has held since 2023. He previously served as bioMérieux’s Chief Operating Officer and led its Asia Pacific region, and earlier spent 14 years at pharmaceutical company Ipsen in senior commercial roles.

How will Pierre Boulud be compensated for serving on STERIS’s board?

For the remainder of the 2025-26 Board term, Pierre Boulud will receive a prorated director fee of $76,989 from STERIS. This compensation will be paid in the form of career restricted stock units granted under the company’s Non-Employee Director Compensation Program, aligning him with shareholder interests.

Did STERIS (STE) issue a press release about Pierre Boulud’s appointment?

Yes. STERIS issued a press release on May 7, 2026 announcing Pierre Boulud’s appointment to the Board of Directors, effective May 5, 2026. The press release is included as Exhibit 99.1 to the report and describes his background and experience in healthcare and diagnostics.

Filing Exhibits & Attachments

5 documents

Press Releases

EX-99.1 EX-99.1 8.8 KB